PFE Pfizer Inc

   By Stephen Nakrosis 
 

Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) said Tuesday that complete results from the first study in ongoing Phase 3 program for tanezumab demonstrated significant improvement in pain and function in osteoarthritis patients.

At 16 weeks of treatment, tanezumab was associated with a significant reduction in pain compared to placebo, the companies said.

The study evaluated the efficacy and safety of subcutaneous administration of tanezumab in patients with osteoarthritis pain treated for 16 weeks. The study met all three co-primary efficacy endpoints, the company said, demonstrating that among patients with moderate-to-severe OA pain of the knee or hip, both dosing regimens of tanezumab were associated with a statistically significant improvement in pain, physical function and patient's global assessment of their OA, compared to placebo.

"The results demonstrated by tanezumab in this study are particularly meaningful, given that patients had moderate-to-severe pain and were unable to achieve adequate pain relief with other treatment options, including opioids and NSAIDs," said Ken Verburg, tanezumab development team leader, Pfizer Global Product Development.

The companies presented their data during a late-breaking oral session at the 2018 American College of Rheumatology/Association of Rheumatology for Health Professionals annual meeting in Chicago.

In 2013, Pfizer and Lilly entered into a worldwide co-development and co-commercialization agreement for the advancement of tanezumab, and in June of last year announced the U.S. Food and Drug Administration granted Fast Track designation for tanezumab for the treatment of OA pain and chronic low back pain.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

October 23, 2018 19:15 ET (23:15 GMT)

Pfizer (NYSE:PFE)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024

Pfizer (NYSE:PFE)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024